ONC – beone medicines ltd. - american depositary shares (US:NASDAQ)
Stock Stats
News
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
BeOne Medicines (NASDAQ:ONC) was given a new $400.00 price target on by analysts at Truist Financial Corporation.
BeOne Medicines (NASDAQ:ONC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Form 4 BeOne Medicines Ltd. For: Dec 10 Filed by: Lee Chan Henry
Form 4 BeOne Medicines Ltd. For: Nov 26 Filed by: Sanders Corazon (Corsee) D.
Form 4 BeOne Medicines Ltd. For: Nov 17 Filed by: Wu Xiaobin
Form 4 BeOne Medicines Ltd. For: Nov 12 Filed by: Wu Xiaobin
Form 4 BeOne Medicines Ltd. For: Nov 12 Filed by: Lee Chan Henry
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.